Eisai is committed to developing and delivering highly beneficial new treatments to help improve the lives of people with epilepsy. The development of AEDs is a major strategic area for Eisai in Europe, the Middle East, Africa, Russia and Oceania (EMEA).
In the EMEA region, Eisai currently has four marketed treatments including:
- Zonegran(R) (zonisamide) as monotherapy and adjunctive therapy in adults,
adolescents and children above the age of 6 with partial-onset seizures, with or
without secondary generalisation. (Zonegran is under license from the originator
Dainippon Sumitomo Pharma)
- Zebinix(R) (eslicarbazepine acetate) as adjunctive therapy in adult patients
with partial-onset seizures, with or without secondary generalisation. (Zebinix is
under license from BIAL)
- Inovelon(R) (rufinamide) for the adjunctive treatment of seizures associated
with Lennox-Gastaut Syndrome in patients >4 years. (Rufinamide was originally
developed by Novartis)
- Fycompa(R) (perampanel) for use as an adjunctive treatment for partial-onset
seizures, with or without secondarily generalised seizures, in patients with epilepsy
aged 12 years and older
About Eisai
Eisai is one of the world's leading research and development (R&D) based pharmaceutical companies and we define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc).
Eisai concentrates its R&D activities in three key areas:
- Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight
loss
- Oncology including: anticancer therapies; tumour regression, tumour
suppression, antibodies, etc.
- Vascular/Immunological reaction including: thrombocytopenia, rheumatoid
arthritis, psoriasis, inflammatory bowel disease
With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 10,000 people worldwide. From its EMEA Knowledge Centre in Hatfield, UK, Eisai has recently expanded its business operations to include Europe, the Middle East, Africa, Russia and Oceania (EMEA). Eisai EMEA has sales and marketing operations in over 20 markets, including the United Kingdom, Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Norway, Portugal, Russia, Slovakia, Spain, Switzerland, Sweden, the Netherlands and the Middle East.
For further information please visit our web site http://www.eisai.co.uk
References
1. Fycompa. Summary of Product Characteristics (updated November 2012) http://www.medicines.org.uk/emc/medicine... [http://www.medicines.org.uk/emc/medicine... ]
2. Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe. http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510... [http://www.ibe-epilepsy.org/downloads/EURO Report 160510.pdf ] [Accessed 18 July 2012].
3. Pugliatti M, et al. Epilepsia 2007: 48(12) 2224-2233.
Date of preparation: December 2013
Job code: perampanel-UK2145
CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson / CharlotteAndrews, +44(0)7908-314-155 / +44(0)7947-231-513,Cressida_Robson@eisai.net, Charlotte_Andrews@eisai.net. Tonic LifeCommunications, Frances Murphy / Nicola Lilley, +44(0)207798-9262 /+44-(0)207-798-9905, frances.murphy@toniclc.com, nicola.lilley@toniclc.com
Andalucía
